Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors

Research summary

mRNA-4359 alone or in combination with pembrolizumab dependent on which arm the participant is assigned. mRNA-4359 dosing: mRNA-4359 will be given at the study site by injection into shoulder or thigh muscle (intramuscular [IM] injection) once every 3 weeks (Day 1 of every cycle). Up to 9 doses of mRNA-4359 will be given in this study, over an approximately 6-month period. Pembrolizumab dosing: If taking pembrolizumab in combination with mRNA-4539, pembrolizumab will be given at the study site by infusion into one of the veins (intravenously, or IV) once every 6 weeks (Day 1 of every other cycle), together with mRNA-4359 during the 9-cycle treatment period (approximately 6 months). On combination dosing days, mRNA-4359 will be given by IM injection before the pembrolizumab infusion. Participants will be assigned to a treatment arm dependent on their type of cancer and any previous treatment received.

Principal Investigator

Prof Mark Middleton

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1007567